These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 25326835)

  • 21. Integrating incretin-based therapy into type 2 diabetes management.
    Brunton SA
    J Fam Pract; 2013 Jun; 62(6 Suppl CME):S1-8. PubMed ID: 23828807
    [No Abstract]   [Full Text] [Related]  

  • 22. An update on exenatide, a novel therapeutic option for patients with type 2 diabetes.
    Crasto W; Khunti K; Davies MJ
    Drugs Today (Barc); 2011 Nov; 47(11):839-56. PubMed ID: 22146227
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Population pharmacokinetics of lyophilized recombinant glucagon-like peptide-1 receptor agonist (recombinant exendin-4, rE-4) in Chinese patients with type 2 diabetes mellitus
.
    Zang YN; Zhang MJ; Wang YT; Wang C; Wang Q; Zheng QS; Ji LN; Guo W; Fang Y
    Int J Clin Pharmacol Ther; 2017 Aug; 55(8):650-658. PubMed ID: 28513427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Incretin-mimetic drugs, an insulin alternative in type 2 diabetes].
    Fabreegas B
    Soins; 2008 Jun; (726):34-7. PubMed ID: 18697336
    [No Abstract]   [Full Text] [Related]  

  • 25. A novel exendin-4 human serum albumin fusion protein, E2HSA, with an extended half-life and good glucoregulatory effect in healthy rhesus monkeys.
    Zhang L; Wang L; Meng Z; Gan H; Gu R; Wu Z; Gao L; Zhu X; Sun W; Li J; Zheng Y; Dou G
    Biochem Biophys Res Commun; 2014 Mar; 445(2):511-6. PubMed ID: 24565847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Glucagon-like peptide-1 receptor agonists].
    Kurose T; Seino Y
    Nihon Rinsho; 2012 May; 70 Suppl 3():689-92. PubMed ID: 22768599
    [No Abstract]   [Full Text] [Related]  

  • 27. [Two breakthroughs in the treatment of type 2 diabetes. Both the receptor agonist and enzyme inhibitors now available in the clinic].
    Ahrén B
    Lakartidningen; 2007 Dec; 104(49-50):3763-4. PubMed ID: 18214322
    [No Abstract]   [Full Text] [Related]  

  • 28. GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations.
    Jespersen MJ; Knop FK; Christensen M
    Expert Opin Drug Metab Toxicol; 2013 Jan; 9(1):17-29. PubMed ID: 23094590
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lixisenatide in Type 2 Diabetes and Acute Coronary Syndrome.
    Derosa G; Maffioli P
    N Engl J Med; 2016 Mar; 374(11):1095. PubMed ID: 26981947
    [No Abstract]   [Full Text] [Related]  

  • 30. Lilly and Amylin to collaborate on potential breakthrough diabetes treatment.
    Walczak IM
    Diabetes Technol Ther; 2002; 4(5):738-9. PubMed ID: 12458567
    [No Abstract]   [Full Text] [Related]  

  • 31. Novel skeletal effects of glucagon-like peptide-1 (GLP-1) receptor agonists.
    Mabilleau G; Pereira M; Chenu C
    J Endocrinol; 2018 Jan; 236(1):R29-R42. PubMed ID: 28855317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Exenatide--an incretin mimetic for treatment of diabetes mellitus type 2].
    Musch A; Heinzl S
    Med Monatsschr Pharm; 2006 Mar; 29(3):86-9. PubMed ID: 16550880
    [No Abstract]   [Full Text] [Related]  

  • 33. Incretin mimetics as emerging treatments for type 2 diabetes.
    Joy SV; Rodgers PT; Scates AC
    Ann Pharmacother; 2005 Jan; 39(1):110-8. PubMed ID: 15562141
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A gut response. The next generation of type 2 drugs.
    Kordella T
    Diabetes Forecast; 2004 Apr; 57(4):39-42. PubMed ID: 15119299
    [No Abstract]   [Full Text] [Related]  

  • 35. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs.
    Chae SY; Jin CH; Shin JH; Son S; Kim TH; Lee S; Youn YS; Byun Y; Lee MS; Lee KC
    J Control Release; 2010 Mar; 142(2):206-13. PubMed ID: 19900495
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New injectable drug approved for type 2 diabetes.
    Mayo Clin Health Lett; 2005 Oct; 23(10):4. PubMed ID: 16411282
    [No Abstract]   [Full Text] [Related]  

  • 37. Exenatide.
    Barnett AH
    Drugs Today (Barc); 2005 Sep; 41(9):563-78. PubMed ID: 16341288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro and in vivo evaluation of a once-weekly formulation of an antidiabetic peptide drug exenatide in an injectable thermogel.
    Yu L; Li K; Liu X; Chen C; Bao Y; Ci T; Chen Q; Ding J
    J Pharm Sci; 2013 Nov; 102(11):4140-9. PubMed ID: 24114868
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of PEGylated exendin-4 released from poly (lactic-co-glycolic acid) microspheres for antidiabetic therapy.
    Lim SM; Eom HN; Jiang HH; Sohn M; Lee KC
    J Pharm Sci; 2015 Jan; 104(1):72-80. PubMed ID: 25407390
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Use of exenatide for weight loss in patients with diabetes.
    Virji A
    Am Fam Physician; 2007 May; 75(9):1304. PubMed ID: 17511061
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.